Getagraph.com logo
S&P 500
(0.24%) 5 112.09 points
Dow Jones
(0.31%) 38 359 points
Nasdaq
(0.29%) 15 975 points
Oil
(-1.42%) $82.66
Gas
(5.77%) $2.03
Gold
(0.30%) $2 354.30
Silver
(0.00%) $27.54
Platinum
(3.90%) $958.05
USD/EUR
(-0.20%) $0.933
USD/NOK
(-0.37%) $10.98
USD/GBP
(-0.51%) $0.796
USD/RUB
(1.68%) $93.42

Sanntidsoppdatering for Bristol-Myers Squibb Co [BMY]

Børs: NYSE Sektor: Healthcare Industri: Drug Manufacturers - General
Sist oppdatert29 apr 2024 @ 20:29
25% discount on Stockinvest.us - Use code: Podcast

-0.48% $ 44.64

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 20:29):
Profile picture for Bristol-Myers Squibb Co

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases...

Stats
Dagens volum 9.35M
Gjennomsnittsvolum 16.16M
Markedsverdi 90.46B
EPS $0 ( 2024-04-25 )
Neste inntjeningsdato ( $1.730 ) 2024-07-25
Last Dividend $0.600 ( 2024-01-04 )
Next Dividend $0 ( N/A )
P/E -14.40
ATR14 $0.0230 (0.05%)
Insider Trading
Date Person Action Amount type
2024-04-01 Shanahan Karin Sell 3 306 Restricted Stock Units
2024-04-01 Shanahan Karin Buy 3 306 Common Stock, $0.10 par value
2024-04-01 Shanahan Karin Sell 1 196 Common Stock, $0.10 par value
2024-03-31 Yale Phyllis R Buy 645 Deferred Share Units
2024-03-31 Storch Gerald L Buy 691 Deferred Share Units
INSIDER POWER
31.44
Last 100 transactions
Buy: 432 337 | Sell: 225 479

Volum Korrelasjon

Lang: -0.15 (neutral)
Kort: -0.71 (moderate negative)
Signal:(39.835) Neutral

Bristol-Myers Squibb Co Korrelasjon

10 Mest positive korrelasjoner
UVV0.926
AJAX0.919
PYN0.908
BSM0.897
HLGN0.892
BAK0.89
HKIB0.888
STZ0.888
SDCI0.886
WE0.884
10 Mest negative korrelasjoner
IRL-0.903
PANA-0.883
IVH-0.878
GOGN-0.878
GOTU-0.872
MGU-0.871
ESM-UN-0.871
STAR-PI-0.869
HWKZ-0.868
SGU-0.866

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Bristol-Myers Squibb Co Korrelasjon - Valuta/Råvare

The country flag 0.03
( neutral )
The country flag 0.11
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag -0.05
( neutral )
The country flag 0.34
( neutral )

Bristol-Myers Squibb Co Økonomi

Annual 2023
Omsetning: $45.01B
Bruttogevinst: $34.31B (76.24 %)
EPS: $3.88
FY 2023
Omsetning: $45.01B
Bruttogevinst: $34.31B (76.24 %)
EPS: $3.88
FY 2022
Omsetning: $46.16B
Bruttogevinst: $36.02B (78.04 %)
EPS: $2.97
FY 2021
Omsetning: $46.39B
Bruttogevinst: $36.45B (78.57 %)
EPS: $3.25

Financial Reports:

No articles found.

Bristol-Myers Squibb Co Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A) 		$0.540
(N/A) 		$0.570
(N/A) 		$0.570
(N/A) 		$0.570
(N/A) 		$0.570
(N/A) 		$0.600
(N/A) 		$0
(N/A) 		$0
(N/A) 		$0
(N/A)

Bristol-Myers Squibb Co Dividend Information - Dividend Knight

Dividend Sustainability Score: 5.65 - average (55.60%) | Divividend Growth Potential Score: 1.211 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $0.00892 1972-07-26
Last Dividend $0.600 2024-01-04
Next Dividend $0 N/A
Payout Date 2024-02-01
Next Payout Date N/A
# dividends 206 --
Total Paid Out $44.07 --
Avg. Dividend % Per Year 2.48% --
Score 4.52 --
Div. Sustainability Score 5.65
Div.Growth Potential Score 1.211
Div. Directional Score 3.43 --
Next Divdend (Est)
 (2024-08-12)
$0.605 Estimate 60.24 %
Dividend Stability
0.96 Excellent
Dividend Score
4.52
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield
1972 $0.0178 0.95%
1973 $0.0482 2.36%
1974 $0.0452 3.25%
1975 $0.0491 3.23%
1976 $0.0536 2.60%
1977 $0.0655 3.24%
1978 $0.0725 3.64%
1979 $0.0856 4.04%
1980 $0.0714 3.31%
1981 $0.106 3.50%
1982 $0.121 3.85%
1983 $0.174 4.36%
1984 $0.190 3.71%
1985 $0.224 3.67%
1986 $0.214 2.74%
1987 $0.250 2.49%
1988 $0.519 5.04%
1989 $0.483 4.57%
1990 $0.521 3.84%
1991 $0.593 3.74%
1992 $0.492 2.34%
1993 $0.685 4.34%
1994 $0.871 6.37%
1995 $0.528 3.80%
1996 $0.893 4.38%
1997 $0.728 2.86%
1998 $0.557 1.24%
1999 $0.820 1.32%
2000 $0.932 1.52%
2001 $1.061 1.56%
2002 $1.400 2.75%
2003 $1.120 4.66%
2004 $0.840 2.86%
2005 $1.120 4.40%
2006 $1.120 4.82%
2007 $1.120 4.25%
2008 $1.550 5.93%
2009 $1.250 5.23%
2010 $0.960 3.75%
2011 $1.320 4.97%
2012 $1.360 3.88%
2013 $1.760 5.38%
2014 $1.450 2.77%
2015 $1.490 2.50%
2016 $1.140 1.70%
2017 $1.560 2.62%
2018 $1.600 2.61%
2019 $1.640 3.13%
2020 $2.29 3.62%
2021 $1.470 2.39%
2022 $2.16 3.49%
2023 $2.28 3.16%
2024 $0.600 1.14%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
LOMA Dividend Knight 2023-06-30 Quarterly 2 5.23% 8.53
VGI Dividend Royal 2024-02-09 Monthly 13 7.36% 8.50
JQC Dividend Royal 2023-11-14 Monthly 22 6.56% 8.50
PHK Dividend Royal 2023-11-10 Monthly 22 6.88% 8.50
PCF Dividend King 2023-12-18 Monthly 38 7.05% 8.50
PVL Dividend King 2023-11-15 Monthly 14 9.37% 8.50
NCV Dividend Royal 2024-02-09 Monthly 22 7.68% 8.50
SBR Dividend Royal 2023-11-14 Monthly 38 7.74% 8.50
MTR Dividend Diamond 2023-10-30 Monthly 39 10.10% 8.50
PDI Dividend Royal 2023-11-10 Monthly 13 7.86% 8.50

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM-0.1351.500-2.70-4.05[0 - 0.5]
returnOnAssetsTTM-0.06211.200-2.07-2.48[0 - 0.3]
returnOnEquityTTM-0.2301.500-3.67-5.50[0.1 - 1]
payoutRatioTTM-0.774-1.000-7.747.74[0 - 1]
currentRatioTTM1.1100.8009.457.56[1 - 3]
quickRatioTTM0.9190.8009.307.44[0.8 - 2.5]
cashRatioTTM0.3611.5009.1010.00[0.2 - 2]
debtRatioTTM0.580-1.5000.338-0.507[0 - 0.6]
interestCoverageTTM10.691.0007.157.15[3 - 30]
operatingCashFlowPerShareTTM6.782.007.7410.00[0 - 30]
freeCashFlowPerShareTTM6.182.006.9110.00[0 - 20]
debtEquityRatioTTM3.48-1.50010.00-10.00[0 - 2.5]
grossProfitMarginTTM0.7571.0000.7150.715[0.2 - 0.8]
operatingProfitMarginTTM0.3061.0005.885.88[0.1 - 0.6]
cashFlowToDebtRatioTTM0.2391.0009.789.78[0.2 - 2]
assetTurnoverTTM0.4600.800-0.268-0.214[0.5 - 2]
Total Score5.65

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-14.761.000-1.5920[1 - 100]
returnOnEquityTTM-0.2302.50-2.36-5.50[0.1 - 1.5]
freeCashFlowPerShareTTM6.182.007.9410.00[0 - 30]
dividendYielPercentageTTM5.221.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM6.782.007.7410.00[0 - 30]
payoutRatioTTM-0.7741.500-7.747.74[0 - 1]
pegRatioTTM-0.03721.500-3.580[0.5 - 2]
operatingCashFlowSalesRatioTTM0.3011.0004.960[0.1 - 0.5]
Total Score1.211

Bristol-Myers Squibb Co

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Om Live Signaler

Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.

Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.